Novo Nordisk has started building its first brand-new manufacturing facility in Denmark since the millennium, saying it plans to spend around DKK 8.5 billion ($1.2 billion) on the plant.

Trump's threat of imposing a tariff on Denmark over desires to acquire Greenland has caught the attention of one of the ...

The firm then sold three of Catalent's plants used to complete the drug manufacturing process to Novo Nordisk for $11 billion as part of the deal, to help the Danish drugmaker ramp up supplies of ...

J&J, AstraZeneca, Novo Nordisk and Roche are among the companies that might take a hit from the soon-to-be-enacted fees, ...

It's still investing billions in spinning up new manufacturing facilities to ensure that supply capacity stops being a constraint on growth. What's more, Novo Nordisk is in exactly the same ...

Novo Nordisk A/S is prepared for potential tariffs ... which has left some manufacturing companies scrambling to react. The US is a key market for Novo’s top products, including Ozempic for ...

In accordance with the trilateral agreement, after approval by the FTC, Novo Nordisk will buy three Catalent plants from Novo Holdings for $11.7 billion. In particular, the deal includes plants in ...

A breakthrough in weight loss medication is on the horizon. While popular drugs like Ozempic and Wegovy are only available as injections, drugmaker Novo Nordisk is working on a more convenient ...

Danish drugmaker Novo Nordisk (NVO) reported fourth quarter ... Novo is working on building new manufacturing sites to combat this, and the closing of the Catalent deal at the end of 2024 that ...